Soleno Therapeutics (FRA:6XC) ROCE % : -56.97% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Soleno Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Soleno Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -56.97%.

Soleno Therapeutics ROCE % Historical Data

The historical data trend for Soleno Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics ROCE % Chart

Soleno Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-63.10

-68.91

-80.75

-111.58

-40.93

Soleno Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-209.74	-195.18	-132.85	-50.19	-56.97

Soleno Therapeutics ROCE % Calculation

Soleno Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-35.46	/	( ( (25.013 - 6.903)	+	(165.694 - 10.55) )	/ 2 )
	=	-35.46	/	( (18.11	+	155.144)	/ 2 )
	=	-35.46	/	86.627
	=	-40.93 %

Soleno Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-84.912	/	( ( (165.694 - 10.55)	+	(155.33 - 12.387) )	/ 2 )
	=	-84.912	/	( ( 155.144	+	142.943 )	/ 2 )
	=	-84.912	/	149.0435
	=	-56.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Soleno Therapeutics (FRA:6XC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Soleno Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Soleno Therapeutics (FRA:6XC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (FRA:6XC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SLNO:USA 6XC:Germany

Address

203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.soleno.life

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.

Soleno Therapeutics (FRA:6XC) Headlines

No Headlines